Clinical Trial

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-11; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2026-03-18
Trial Details
NCT Number NCT07351968
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Moderate Pain in Knee Osteoarthritis, Severe Pain in Knee Osteoarthritis
Enrollment 200 participants
Start Date 2026-03-10
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-19